At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Theracurmin HPdrug
Likely dose
Theracurmin HP 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-center, 6-month Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)
In Brief
A Phase 2 clinical trial evaluating Theracurmin HP for Amyotrophic Lateral Sclerosis. Completed, enrolled 100 participants across 1 site.
Detailed Summary
This will be a 6-month, widely inclusive, virtual, single-center, open-label pilot trial utilizing a historical control group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartAug 2020
Primary CompletionAug 2022
TodayJul 2026
First PostedAug 5, 2020
Enrollment StartAug 28, 2020
Primary CompletionAug 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.9 years ago
Interventions
Theracurmin HPdrug
The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment